Dr. Haiyang Feng 冯海洋
Chief Physician
Department of Colorectal Surgical Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive treatment of colorectal cancer. Neoadjuvant therapy followed by surgery for locally advanced rectal cancer. Comprehensive treatment for advanced colorectal cancer.
Dr. Feng graduated from Zhejiang Medical University in 1993 and Fujian Medical University in 1999. Working at Zhejiang Cancer Hospital since 1999, Dr. Feng has over 20 years of experience in colorectal surgery. Research focuses on minimally invasive surgery and comprehensive treatment. Dr. Feng leads one Zhejiang Provincial Natural Science Foundation project and four department-level projects.
Professional roles
- Standing Committee Member, Professional Committee on Gastrointestinal Polyps and Precancerous Lesions, China Anti-Cancer Association
- Member, Laparoscopy Group, Colorectal Cancer Professional Committee, China Anti-Cancer Association
- Member, Anorectal Surgery Association, Zhejiang Medical Association
- Member, Tumor Nutrition Professional Committee, Zhejiang Nutrition Society
Name order: in Chinese the family name comes first (Feng Haiyang). Papers usually list the name as Haiyang Feng or Feng H.
Selected publications
21 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Biol Int, 2020 (senior author): Fibronectin promotes tumor cells growth and drugs resistance through a CDC42-YAP-dependent signaling pathway in colorectal cancer. PubMed 32437085
- Biosci Rep, 2019 (first author): The association between IL-17 gene variants and risk of colorectal cancer in a Chinese population: A case-control study. PubMed 31682719
- Chem Biol Drug Des, 2017 (first author): Preparation, characterization, and in vivo study of rhein solid lipid nanoparticles for oral delivery. PubMed 28432812
- Biomol Ther (Seoul), 2014 (first author): Formulation and evaluation of irinotecan suppository for rectal administration. PubMed 24596626
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion